You have a heart attack. Emergency services arrive. Surgeons clear the blocked artery in time. By every medical measure, the intervention worked.
And yet, for up to half of all heart attack patients, something still goes wrong.
Even after the main coronary artery is reopened, tiny blood vessels deeper in the heart muscle — the capillaries — can remain constricted. Blood can't reach the surrounding tissue. The heart is still starving. This is called 'no-reflow,' and it significantly raises the risk of death or hospitalisation for heart failure within the following year.
Doctors have known about no-reflow for decades. They have had almost no way to reliably treat it.
New research published in *Nature Communications* on March 3, 2026, may have just changed that.
A team led by Dr Svetlana Mastitskaya at the University of Bristol and University College London has found that GLP-1 weight-loss drugs — the class of medications that includes Ozempic, Wegovy, and Mounjaro — can reverse the cellular mechanism responsible for no-reflow. And the implications are significant.
**What causes no-reflow?**
The Bristol team's earlier research had already identified the culprit: tiny contractile cells called pericytes that wrap around coronary capillaries. When the heart is deprived of oxygen during a heart attack, pericytes contract sharply — constricting the capillaries they surround and blocking blood flow. When surgeons clear the main artery and blood rushes back in, it hits a wall of tightly squeezed micro-vessels and can't get through.
This new study investigated whether GLP-1 drugs — already known to reduce serious cardiovascular events — might work through this exact mechanism.
The answer was yes.
In laboratory models, GLP-1 treatment relaxed pericyte constriction, restoring blood flow through the coronary capillaries even after an ischaemic event. The drugs appear to act directly on pericytes in a way that none of the existing cardiovascular treatments do.
'Our latest findings are surprising and very exciting,' said Dr Mastitskaya, lead author and Senior Lecturer in Cardiovascular Regenerative Medicine at Bristol Medical School. 'We have shown that GLP-1 drugs can reduce the constriction of the heart's capillaries during a heart attack — potentially protecting the heart muscle at the most critical moment.'
**Why this matters — beyond the weight loss headline**
GLP-1 drugs have already demonstrated cardiovascular benefits in large clinical trials. The LEADER trial for liraglutide and the SUSTAIN-6 trial for semaglutide showed reduced rates of major cardiovascular events in patients with type 2 diabetes. But the *mechanisms* behind these benefits have been poorly understood.
This research provides one compelling explanation: these drugs may be directly protecting the heart's microvasculature at the moment it is most vulnerable.
If that holds in human clinical trials, the implication is significant. GLP-1 drugs could be administered during or immediately after a heart attack to prevent the no-reflow complication — not as an adjunct to weight management, but as an acute cardiac intervention in their own right.
Around 800,000 people in the US have a heart attack each year. If half experience some degree of no-reflow, that is 400,000 cases annually where this treatment approach could potentially make a material difference to survival and recovery.
The research is still at the preclinical stage and requires validation in human trials. But the mechanistic clarity is striking — and the drugs already exist, are already approved, and have established safety profiles.
For the first time, medicine may have a credible answer to one of cardiology's longest-standing unsolved problems. ❤️